Market narrative
Move between stock news, official company releases, crypto, and FX without losing the path back to ticker research.
BALA CYNWYD, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its second quarter 2026 operating and financial results.
Press releases
Infobahn, a subsidiary of TNL Mediagene, has officially formed a partnership with Miro The partnership focuses on delivering innovative solutions for organizational design and human resource development to enterprise clients in Japan by leveraging Miro's visual workspace The agreement supports TNL Mediagene's strategy to expand AI-powered services within its digital studio business To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/12240/307890_bdff7b32a4258946_001full.jpg Tokyo, Japan--(Newsfile Corp. - August 4, 2026) - TNL Mediagene (NASDAQ: TNMG) (the "Company"), a technology and digital media company providing AI-driven advertising, marketing technology, content commerce and data analytics solutions, and operating multi-language digital media brands across Asia, today announced that its wholly owned subsidiary, Infobahn, entered into a partnership with Miro, AI-powered innovation workspace company, consistent with the Company's FY2026 business strategy to expand AI-powered services within its digital studio business. This strategic partnership combines Infobahn's extensive expertise in design thinking, corporate innovation, and B2B consulting with Miro's industry-leading visual workspace.
12% Top-Line Growth Driven by 6% Publishing and 35% Recorded Music Growth NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Reservoir Media, Inc. (NASDAQ: RSVR) ("Reservoir" or the "Company"), an award-winning independent music company, today announced financial results for the first quarter of fiscal 2027 ended June 30, 2026. Recent Highlights: Revenue of $41.5 million, increased 6% organically, or 12% including acquisitions year-over-year Music Publishing Revenue rose 6% year-over-year Recorded Music Revenue increased 35% year-over-year Operating Income of $5.4 million, decreased 1% year-over-year OIBDA ("Operating Income Before Depreciation & Amortization") of $13.7 million, an increase of 7% year-over-year Net Loss of ($0.5) million, or $0.00 per share, compared to a net loss of ($0.6) million, or ($0.01) per share in the year-ago period Adjusted EBITDA of $15.7 million, up 13% year-over-year Invested in two new complementary strategic partnerships in Latin music: Announced the acquisition of the catalog of independent Latin label Nacional Records, along with the catalog of its publishing arm, Canciones Nacionales.
Proceeds of $50.1 million will be used to support the Company's advancement of CMP-002 for the treatment of SYNGAP1-related disorder Proceeds of $50.1 million will be used to support the Company's advancement of CMP-002 for the treatment of SYNGAP1-related disorder
– Quarterly Revenue of $163.4 million – – Income from Operations of $18.7 million – – Net Income of $12.1 million – – Adjusted EBITDA1 of $31.6 million – – Backlog and Awarded Orders of $801.4 million – – Provides Third Quarter and Reaffirms Full-year Outlook – PORTLAND, Tenn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a global leader in electrical infrastructure solutions for the energy transition market, today announced results for its second quarter ended June 30, 2026.
VANCOUVER, BC / ACCESS Newswire / August 4, 2026 / CoTec Holdings Corp. (TSXV:CTH)(OTCQX:CTHCF) ("CoTec" or the "Company") is pleased to announce that MagIron LLC ("MagIron"), a US based company in which it owns an approximately 17% fully diluted equity interest, has announced the completion of a positive pig iron concept and economic study for its Minnesota based iron ore resources and iron ore concentrator and Indiana based pelletizing facilities (the "Study"). The Study was completed by Primetals Technologies ("Primetals"), a recognized global leader in metallurgical plant solutions and iron and steelmaking technologies, evaluating the development of large-scale granulated pig iron production to be integrated with MagIron's existing facilities.
Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive approximately $453 million in future milestones associated with the STAT6 program, as well as potential royalties, and retains a U.S. co-development and co-promotion option BRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that it has earned a $10 million milestone payment following the initiation by its collaborator, Sanofi, of the Phase 1 first-in-human clinical trial of SAR448272/NX-3911, an oral STAT6 degrader.
CALGARY, AB, Aug. 4, 2026 /PRNewswire/ -- NG Energy International Corp. ("NGE" or the "Company") (TSX: GASX) (OTCQX: GASXF) is pleased to announce that it has received total proceeds of C$26,509,500.00 from the exercise of 29,455,000 common share purchase warrants issued on July 31, 2023 (the "July 2026 Warrants"), which have an exercise price of $0.90 each, with approximately C$22 million received since the end of Q1 2026. The Company originally issued 35,000,000 July 2026 Warrants in connection with the Company's private placement of senior secured convertible debenture units, which was completed on July 31, 2023.
Appoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guidance RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its second quarter 2026 financial results.
FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA with a fireside chat at 1:00pm ET (link here).
ST. LOUIS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- BellRing Brands, Inc. (NYSE:BRBR) (“BellRing”), a holding company operating in the global proactive wellness category, today reported results for the third fiscal quarter ended June 30, 2026. Highlights: Third quarter net sales of $570.4 million , up 4% year-over-year Operating profit of $65.4 million , net earnings of $34.2 million and Adjusted EBITDA* of $78.3 million , each of which included a pre-tax $10 million inventory-related charge Updated fiscal year 2026 net sales outlook of $2.335-$2.375 billion and Adjusted EBITDA* outlook of $275-$295 million, inclusive of full year pre-tax $28 million unfavorable impact of inventory-related actions *Adjusted EBITDA is a non-GAAP measure.
GOLETA, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Aeluma, Inc. (NASDAQ: ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum, announced today it has appointed Jason Taylor, M.S.
Highlights Net income during the second quarter of 2026 decreased $278 thousand, or 12.7%, to $1.9 million, or $0.54 per diluted share, from $2.2 million, or $0.62 per diluted share, in the 2025 period. The decrease reflects $1.5 million of professional services expense related to the pending acquisition by OppFi Inc. Net income during the first six months of 2026 increased $122 thousand, or 3.1%, to $4.1 million, or $1.15 per diluted share, from $3.9 million or $1.11 per diluted share in the 2025 period.
Partnership brings Nociscan for chronic low back pain to one of the nation's leading neurosurgery and spine care networks Goodman Campbell Brain & Spine is recognized nationally for its role in neurosurgery training and clinical research Availability of Nociscan in Indiana reflects Company's focus on expansion and adding to its growing base of provider sites across the country BROOMFIELD, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, marking the first site in Indiana to offer the technology.
MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced that the Board of Directors (the “Board”) has appointed Heather Getz as Chief Executive Officer and Director, effective today.
TRISO-X has acquired approximately 70 additional acres adjacent to its Oak Ridge fuel fabrication campus, expanding the site from 125 acres to 180 acres.
Same-Restaurant Sales Growth of 3.4% Total revenues increased 15.2% Net income of $2.3 million and Adjusted EBITDA of $34.5 million 18 new System-wide restaurants opened in 15 states
DISA Uranium Receives US$105 million in Financing Commitments, Backed by Consortium of Leading Strategic Investors TORONTO, Aug. 4, 2026 /PRNewswire/ -- IsoEnergy Ltd. ("IsoEnergy") (NYSE American: ISOU) (TSX: ISO) is pleased to announce that it has entered into a definitive agreement with DISA Technologies, Inc. ("DISA") to create DISA Uranium™ Corporation ("DISA Uranium" or the "Company"), a new technology-enabled U.S. uranium company positioned to strengthen domestic uranium supply and support the growing demand for secure, U.S.-sourced nuclear fuel.
Fiscal Year 2026 Recurring revenues grew 8% on a reported and constant currency basis Diluted EPS was $9.60 and Adjusted EPS grew 12% to $9.60 Closed sales rose to $305 million Raising annual dividend by 12% to $4.36, 20th consecutive annual dividend increase Fiscal year 2027 guidance calls for 6-8% Recurring revenue growth constant currency and 8-12% Adjusted EPS growth NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Broadridge Financial Solutions, Inc. (NYSE:BR) today reported financial results for the fourth quarter and fiscal year 2026. Results compared with the same period last year were as follows: Summary Financial Results Fourth Quarter Fiscal Year Dollars in millions, except per share data 2026 2025 Change 2026 2025 Change Recurring revenues $1,542 $1,424 8 % $4,878 $4,508 8 % Constant currency growth (Non-GAAP) 8 % 8 % Total revenues $2,220 $2,065 7 % $7,477 $6,889 9 % Operating income $546 $499 10 % $1,301 $1,189 9 % Margin 24.6 % 24.1 % 17.4 % 17.3 % Adjusted Operating income (Non-GAAP) $598 $558 7 % $1,535 $1,411 9 % Margin (Non-GAAP) 26.9 % 27.0 % 20.5 % 20.5 % Diluted EPS $3.44 $3.16 9 % $9.60 $7.10 35 % Adjusted EPS (Non-GAAP) $3.82 $3.55 8 % $9.60 $8.55 12 % Closed sales $158 $114 39 % $305 $288 6 % "Broadridge is delivering strong results today while positioning our company for an exciting digital, agentic, and tokenized future," said Tim Gokey, Broadridge's CEO.
Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 Clinical revenue increased 22.6% sequentially in Q2 2026; Excluding Clinical acquisitions that closed in Q2 2026, Clinical revenue increased 15.1% sequentially driven by a 23.8% increase in Transplant Clinical revenue Q2 2026 net loss from continuing operations of $(10.5) million or (14.5)% of revenue Adjusted EBITDA (1) of $7.9 million in Q2 2026; Adjusted EBITDA margin of 10.9% Cash flow from operating activities was $5.7 million in Q2 2026; Free Cash Flow (1) was $2.9 million in Q2 2026 Completed bolt-on acquisitions of Louisville Perfusion Services, Heart and Lung Transplant National Recovery Program and Ohio Valley Perfusion Associates during Q2 2026 Signed agreement to take over Statline's Transplant Center Organ Placement customer relationships on a rolling basis over the next year NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the second quarter ended June 30, 2026. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.
